Context Therapeutics (CNTX) said Tuesday it dosed the first patient in the phase 1 study of CTIM-76, its lead drug candidate targeting Claudin 6-positive gynecologic and testicular cancers.
Initial data from the trial is expected to be released in H1 2026, the company said.
The phase 1 trial seeks to evaluate the safety and efficacy of CTIM-76 in patients with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer.
Up to 70 patients will be enrolled in the phase 1 trial to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity, including response rate, duration, and disease control, the company said.
Shares of Context Therapeutics were up 1% in after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。